

Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder

NCT07184840

Status	RECRUITING
Phase	Phase 2
Sponsor	Tianjin Medical University General Hospital
Enrollment	110 participants

Key Eligibility Criteria

Inclusion (6)

- Anti-AQP4 antibody seropositive.
- Male or female patients ≥18 years old
- Body weight ≥ 35 kg
- Acute optic neuritis and/or transverse myelitis enrolled within 28 days from the attack, with a change in neurological exam that meet an increase of OSIS at least 2 points of baseline compared to that of prior attack.
- A female subject is eligible to enter the trial if she is:
... and 1 more (see full listing online)

Exclusion (7)

- Use of IVIg within 3 weeks prior to screening
- Unresolved meningococcal infection
- Any systemic bacterial or other infection which is clinically significant in the opinion of the Investigator and has not been treated with appropriate antibiotics
- Participation in any other investigational drug study or was exposed to an investigational drug or device within 30 days of screening.
- Has previously received treatment with eculizumab
... and 2 more (see full listing online)

Locations (1 total)

Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality, China